CorMedix Q1 revenue surges to $127.4M driven by DefenCath and Melinta sales, with organic growth outpacing TDAPA expiration concerns.

Eton Pharmaceuticals Q1 sales rose 73% driven by rare-disease portfolio expansion, with full-year guidance raised to $120 million.

Senti Biosciences advances CAR-NK program into pivotal AML trial with FDA RMAT designation and single-arm registrational pathway support.

Biogen completes Apellis Pharmaceuticals acquisition for $41 per share, gaining complement therapy assets and nephrology infrastructure for felzartamab launch.

Eli Lilly's $300M acquisition of CrossBridge Bio targets dual-payload ADCs — a manufacturing cost doubler that signals a bold...

Emrosi revenue tripled in Q1 2026 as Journey Medical reaches 85% payer coverage and achieves positive adjusted EBITDA.

Humacyte posts fivefold Symvess revenue growth in Q1 2026 while restructuring operations ahead of critical Phase 3 interim data.

Can-Fite advances namodenoson into Phase 2b study for pancreatic cancer, seeking a pharma partner to fund the combination trial...

Orforglipron's 72-week Phase 3 data, SURMOUNT-5's head-to-head verdict, and Roche's oral small molecule push signal a $87B market restructuring...

Setmelanotide BMI Reduction reaches 19.6% at nine months in acquired hypothalamic obesity patients, with significant cardiometabolic improvements shown.